Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis

Journal of Medicinal Chemistry

Volumn 56, Issue 24, 2013, Pages 9861-9873

  Vodnala, Suman K ^a   Lundbäck, Thomas ^a,d   Yeheskieli, Esther ^a   Sjöberg, Birger ^a,d   Gustavsson, Anna Lena ^a,d   Svensson, Richard ^a,b,c   Olivera, Gabriela C ^a   Eze, Anthonius A ^c   De Koning, Harry P ^c   Hammarström, Lars G J ^a,c   Rottenberg, Martin E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d Chemical Biology Consortium Sweden   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1A,1B,2-11; 2 (2 HYDROXYETHYLAMINO)CORDYCEPIN; 2 (6 AMINO 2 FLUORO 9H PURIN 9 YL) 5 (HYDROXYMETHYL)TETRAHYDROFURAN 3 OL; 2 CHLOROCORDYCEPIN; 2 FLUOROCORDYCEPIN; 5 (HYDROXYMETHYL) 2 (9H PURIN 9 YL)TETRAHYDROFURAN 3 OL; [4 ACETOXY 5 (6 AMINO 9H PURIN 9 YL)TETRAHYDROFURAN 2 YL)METHYLACETATE; ADENOSINE KINASE; ANTITRYPANOSOMAL AGENT; ARABINOSE; CORDYCEPIN DERIVATIVE; RIBOSE; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRYPANOSOMA BRUCEI;

EID: 84891293496     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401530a     Document Type: Article

References (56)

1. Bacchi, C. J. Chemotherapy of human african trypanosomiasis Interdiscip. Perspect. Infect. Dis. 2009, 2009, 1-5
2. Kristensson, K.; NygaÌŠrd, M.; Bertini, G.; Bentivoglio, M. African trypanosome infections of the nervous system: parasite entry and effects on sleep and synaptic functions Prog. Neurobiol. 2010, 91, 152-171
3. Maurice, J. New WHO plan targets the demise of sleeping sickness Lancet 2013, 381, 13-14
4. Stich, A.; Barrett, M. P.; Krishna, S. Waking up to sleeping sickness Trends Parasitol. 2003, 19, 195-197
5. Bacchi, C. J.; Berens, R. L.; Nathan, H. C.; Klein, R. S.; Elegbe, I. A; Rao, K. V; McCann, P. P.; Marr, J. J. Synergism between 9-deazainosine and dl -alpha-difluoromethylornithine in treatment of experimental African trypanosomiasis Antimicrob. Agents Chemother. 1987, 31, 1406-1413
6. Simarro, P. P.; Franco, J.; Diarra, A.; Postigo, J. a R.; Jannin, J. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis Parasitology 2012, 139, 842-846
7. Priotto, G.; Kasparian, S.; Mutombo, W.; Ngouama, D.; Ghorashian, S.; Arnold, U.; Ghabri, S.; Baudin, E.; Buard, V.; Kazadi-Kyanza, S.; Ilunga, M.; Mutangala, W.; Pohlig, G.; Schmid, C.; Karunakara, U.; Torreele, E.; Kande, V. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial Lancet 2009, 374, 56-64
8. Alirol, E.; Schrumpf, D.; Amici Heradi, J.; Riedel, A.; de Patoul, C.; Quere, M.; Chappuis, F. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo Clin. Infect. Dis. 2013, 56, 195-203
9. Baker, N.; Alsford, S.; Horn, D. Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6 Mol. Biochem. Parasitol. 2011, 176, 55-57
10. Wilkinson, S. R.; Taylor, M. C.; Horn, D.; Kelly, J. M.; Cheeseman, I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 5022-5027
11. De Koning, H. P.; Bridges, D. J.; Burchmore, R. J. S. Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy FEMS Microbiol. Rev. 2005, 29, 987-1020
12. Sufrin, J. R.; Spiess, A. J.; Marasco, C. J.; Rattendi, D.; Bacchi, C. J. Novel trypanocidal analogs of 5′-(methylthio)-adenosine Antimicrob. Agents Chemother. 2008, 52, 211-219
13. Vodnala, S. K.; Ferella, M.; Lundén-Miguel, H.; Betha, E.; van Reet, N.; Amin, D. N.; Oberg, B.; Andersson, B.; Kristensson, K.; Wigzell, H.; Rottenberg, M. E. Preclinical assessment of the treatment of second-stage African trypanosomiasis with cordycepin and deoxycoformycin PLoS Neglected Trop. Dis. 2009, 3, e495
14. Rodenko, B.; van der Burg, A. M.; Wanner, M. J.; Kaiser, M.; Brun, R.; Gould, M.; de Koning, H. P.; Koomen, G.-J. 2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities Antimicrob. Agents Chemother. 2007, 51, 3796-3802
15. Williamson, J.; Scott-Finnigan, T. Trypanocidal activity of antitumor antibiotics and other metabolic inhibitors Antimicrob. Agents Chemother. 1978, 13, 735-744
16. Mäser, P.; Vogel, D.; Schmid, C.; Räz, B.; Kaminsky, R. Identification and characterization of trypanocides by functional expression of an adenosine transporter from Trypanosoma brucei in yeast J. Mol. Med. 2001, 79, 121-127
17. Rottenberg, M. E.; Masocha, W.; Ferella, M.; Petitto-Assis, F.; Goto, H.; Kristensson, K.; McCaffrey, R.; Wigzell, H. Treatment of African trypanosomiasis with cordycepin and adenosine deaminase inhibitors in a mouse model J. Infect. Dis. 2005, 192, 1658-1665
18. Siev, M.; Weinberg, R.; Penman, S. The selective interruption of nucleolar RNA synthesis in HeLa cells by cordycepin J. Cell Biol. 1969, 41, 510-520
19. Müller, W.; Seibert, G.; Beyer, R.; Breter, H. Effect of cordycepin on nucleic acid metabolism in L5178Y cells and on nucleic acid-synthesizing enzyme systems Cancer Res. 1977, 37, 3824-3833
20. Holbein, S.; Wengi, A.; Decourty, L.; Freimoser, F. M.; Jacquier, A.; Dichtl, B. Cordycepin interferes with 3′ end formation in yeast independently of its potential to terminate RNA chain elongation RNA 2009, 15, 837-849
21. Lüscher, A.; Onal, P.; Schweingruber, A.-M.; Mäser, P. Adenosine kinase of Trypanosoma brucei and its role in susceptibility to adenosine antimetabolites Antimicrob. Agents Chemother. 2007, 51, 3895-3901
22. Vodnala, M.; Fijolek, A.; Rofougaran, R.; Mosimann, M.; Mäser, P.; Hofer, A. Adenosine kinase mediates high affinity adenosine salvage in Trypanosoma brucei J. Biol. Chem. 2008, 283, 5380-5388
23. Barrett, M. P.; Gilbert, I. H. Targeting of toxic compounds to the trypanosome's interior Adv. Parasitol. 2006, 63, 125-183
24. Geiser, F.; Lüscher, A.; de Koning, H. P.; Seebeck, T.; Mäser, P. Molecular pharmacology of adenosine transport in Trypanosoma brucei: P1/P2 revisited Mol. Pharmacol. 2005, 68, 589-595
25. De Koning, H. P.; Jarvis, S. M. Adenosine transporters in bloodstream forms of Trypanosoma brucei brucei: substrate recognition motifs and affinity for trypanocidal drugs Mol. Pharmacol. 1999, 56, 1162-1170
26. Airhart, M. J.; Robbins, C. M.; Knudsen, T. B.; Church, J. K.; Skalko, R. G. Developing allantois is a primary site of 2′-deoxycoformycin toxicity Teratology 1996, 53, 361-373
27. Wei, H.-P.; Ye, X.-L.; Chen, Z.; Zhong, Y.-J.; Li, P.-M.; Pu, S.-C.; Li, X.-G. Synthesis and pharmacokinetic evaluation of novel N -acyl-cordycepin derivatives with a normal alkyl chain Eur. J. Med. Chem. 2009, 44, 665-669
28. Lynch, T. P.; Paran, J. H.; Paterson, A. R. P. Therapy of mouse leukemia L1210 with combinations of nebularine and nitrobenzylthioinosine-5′- monophosphate Cancer Res. 1981, 41, 560-565
29. Gillerman, I.; Fischer, B. Investigations into the origin of the molecular recognition of several adenosine deaminase inhibitors J. Med. Chem. 2011, 54, 107-121
30. Wallace, L. J. M.; Candlish, D.; De Koning, H. P. Different substrate recognition motifs of human and trypanosome nucleobase transporters. Selective uptake of purine antimetabolites J. Biol. Chem. 2002, 277, 26149-26156
31. Dickinson, M.; Holly, F. 3′-Deoxynucleosides. V. 3′-Deoxy-2-fluoroadenosine J. Med. Chem. 1967, 275, 1165-1167
32. Wilson, D.; Rudolph, F.; Quiocho, F. Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations Science 1991, 252, 1278-1284
33. Brockman, R. W.; Schabel, F. M.; Montgomery, J. A. Biological activity of 9-beta- d -arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta- d -arabinofuranosyladenine Biochem. Pharmacol. 1977, 26, 2193-2196
34. Hansske, F.; Robins, M. Regiospecific and stereoselective conversion of ribonucleosides to 3′-deoxynucleosides. A high yield three-stage synthesis of cordycepin from adenosine Tetrahedron Lett. 1985, 4295-4298
35. Robins, M.; Hansske, F.; Low, N.; Park, J. A mild conversion of vicinal diols to alkenes. Efficient transformation of ribonucleosides into 2′-ene and 2′,3′-dideoxynucleosides Tetrahedron Lett. 1984, 25, 367-370
36. Robins, M. J.; Wilson, J. S.; Madej, D.; Low, N. H.; Hansske, F.; Wnuk, S. F. Nucleic acid related compounds. 88. Efficient conversions of ribonucleotides into the 2′,3′-anhydro, 2′(and 3′)-deoxy, 2′,3′-didehydro-2′,3′-dideoxy, and 2′,3′-dideoxynucleoside analogues J. Org. Chem. 1995, 60, 7902-7908
37. Nicolaou, K. C.; Ellery, S. P.; Rivas, F.; Saye, K.; Rogers, E.; Workinger, T. J.; Schallenberger, M.; Tawatao, R.; Montero, A.; Hessell, A.; Romesberg, F.; Carson, D.; Burton, D. Synthesis and biological evaluation of 2′,4′- and 3′,4′-bridged nucleoside analogues Bioorg. Med. Chem. 2011, 19, 5648-5669
38. Mäser, P.; Sütterlin, C.; Kralli, A.; Kaminsky, R. A nucleoside transporter from Trypanosoma brucei involved in drug resistance Science 1999, 285, 242-244
39. Carter, N.; Barrett, M.; Koning, H. A drug resistance determinant in Trypanosoma brucei Trends Microbiol. 1999, 1997-1999
40. Lüscher, A.; De Koning, H. P.; Mäser, P. Chemotherapeutic strategies against Trypanosoma brucei: drug targets vs. drug targeting Curr. Pharm. Des. 2007, 13, 555-567
41. Collar, C.; Al-Salabi, M.; Stewart, M. Predictive computational models of substrate binding by a nucleoside transporter J. Biol. Chem. 2009, 284, 34028-34035
42. Munday, J. C.; Rojas López, K. E.; Eze, A. A.; Delespaux, V.; Van Den Abbeele, J.; Rowan, T.; Barrett, M. P.; Morrison, L. J.; de Koning, H. P. Functional expression of TcoAT1 reveals it to be a P1-type nucleoside transporter with no capacity for diminazene uptake Int. J. Parasitol. 2013, 3, 69-76
43. Matovu, E.; Geiser, F.; Schneider, V.; Mäser, P.; Enyaru, J. C.; Kaminsky, R.; Gallati, S.; Seebeck, T. Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy Mol. Biochem. Parasitol. 2001, 117, 73-81
44. Kalckar, H. Differential spectrophotometry of purine compounds by means of specific enzymes II. Determination of adenine compounds J. Biol. Chem. 1947, 445-459
45. Antonino, L. C.; Wu, J. C. Human IMP dehydrogenase catalyzes the dehalogenation of 2-fluoro- and 2-chloroinosine 5′-monophosphate in the absence of NAD Biochemistry 1994, 33, 1753-1759
46. Bergström, C. A.; Strafford, M.; Lazorova, L.; Avdeef, A.; Luthman, K.; Artursson, P. Absorption classification of oral drugs based on molecular surface properties J. Med. Chem. 2003, 46, 558-570
47. Francom, P.; Janeba, Z. Nucleic acid related compounds. 116. Nonaqueous diazotization of aminopurine nucleosides. Mechanistic considerations and efficient procedures with tert -butyl J. Org. Chem. 2002, 67, 6788-6796
48. Kawana, M.; Nishikawa, M.; Yamasaki, N.; Kuzuhara, H. Facile transformation of beta- d -ribofuranosyl purines and pyrimidines into their respective 3′-deoxy- threo -pentofuranosyl nucleosides J. Chem. Soc., Perkin Trans. 1 1989, 1593-1596
49. Vodnala, S. K.; Lundbäck, T.; Sjöberg, B.; Svensson, R.; Rottenberg, M. E.; Hammarström, L. G. J. In vitro and in vivo activity of 2-aminopyrazines/2-aminopyridines in experimental models of human African trypanosomiasis Antimicrob. Agents Chemother. 2013, 57, 1012-1018
50. Bridges, D.; Gould, M.; Nerima, B. Loss of the high-affinity pentamidine transporter is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes Mol. Pharmacol. 2007, 71, 1098-1108
51. Matovu, E.; Stewart, M.; Geiser, F.; Brun, R. Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei Eukaryotic Cell 2003, 2, 1003-1008
52. Natto, M. J.; Wallace, L. J. M.; Candlish, D.; Al-Salabi, M. I.; Coutts, S. E.; de Koning, H. P. Trypanosoma brucei: expression of multiple purine transporters prevents the development of allopurinol resistance Exp. Parasitol. 2005, 109, 80-86
53. Kelly, M. A.; Vestling, M. M.; Murphy, C. M.; Hua, S.; Sumpter, T.; Fenselau, C. Primary structure of bovine adenosine deaminase J. Pharm. Biomed. Anal. 1996, 14, 1513-1519
54. Waters, N. J.; Jones, R.; Williams, G.; Sohal, B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding J. Pharm. Sci. 2008, 97, 4586-4595
55. Houston, J. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance Biochem. Pharmacol. 1994, 47, 1469-1479
56. Hubatsch, I.; Ragnarsson, E. G. E.; Artursson, P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers Nat. Protoc. 2007, 2, 2111-2119